Fulgent Genetics Inc (NASDAQ:FLGT) CFO Paul Kim sold 12,389 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $11.50, for a total value of $142,473.50. Following the completion of the sale, the chief financial officer now directly owns 412,250 shares of the company’s stock, valued at approximately $4,740,875. The transaction was disclosed in a document filed with the SEC, which is available through this link.

FLGT traded down $0.58 on Wednesday, reaching $10.41. 79,053 shares of the stock were exchanged, compared to its average volume of 24,338. The firm’s 50-day moving average is $7.28. Fulgent Genetics Inc has a fifty-two week low of $3.02 and a fifty-two week high of $12.44. The company has a quick ratio of 11.33, a current ratio of 11.33 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $207.33 million, a price-to-earnings ratio of -54.79 and a beta of 1.47.

Fulgent Genetics (NASDAQ:FLGT) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.02 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.06. Fulgent Genetics had a negative return on equity of 4.70% and a negative net margin of 12.38%. The company had revenue of $8.42 million during the quarter, compared to analysts’ expectations of $6.42 million. As a group, equities analysts anticipate that Fulgent Genetics Inc will post -0.01 earnings per share for the current year.

An institutional investor recently raised its position in Fulgent Genetics stock. BlackRock Inc. boosted its position in shares of Fulgent Genetics Inc (NASDAQ:FLGT) by 15.9% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 16,607 shares of the company’s stock after acquiring an additional 2,281 shares during the quarter. BlackRock Inc. owned about 0.09% of Fulgent Genetics worth $111,000 at the end of the most recent reporting period. 6.78% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have recently weighed in on the company. Piper Jaffray Companies raised their price objective on Fulgent Genetics from $5.30 to $9.50 and gave the stock a “neutral” rating in a research report on Tuesday, August 6th. Zacks Investment Research cut Fulgent Genetics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Finally, Credit Suisse Group cut Fulgent Genetics from an “outperform” rating to a “neutral” rating in a research report on Friday, April 26th.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes.

See Also: Put Option Volume

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.